ARCADIA, Calif. (April 16, 2007)—StemCyte, Inc., a privately-held stem cell therapy and cord blood company, with highly-accredited processing and storage facilities in both the U.S. and Taiwan, recently released its 500th cord blood stem cell shipment for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell products. StemCyte has now provided cord blood stem cell shipments to over 130 transplant centers worldwide across 6 continents, with the number of shipments released for transplantation increasing rapidly. StemCyte’s therapeutic products have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders.

               "StemCyte is committed to building the largest and most racially diverse cord blood bank in the world," says StemCyte's CEO Ken Giacin. "We will strive to over-deliver on our contract to help build the National Cord Blood Inventory in the United States while looking to help build cord blood banks in underserved countries around the world. StemCyte expects to grow rapidly in terms of the number of transplant centers that we serve and the number of patients whose lives are saved by our products.”

            “We are very pleased with the growing vote of confidence that is being extended to StemCyte by transplant physicians around the world,” said Lawrence D. Petz, M.D., Chief Medical Officer, StemCyte International Cord Blood Center, and Emeritus Professor of Pathology and Laboratory Medicine, UCLA Medical Center.  “Our consistently excellent one-year patient survival data continue to point to both the increasing level of transplant physician care as well as to the high degree of efficacy of our cord blood products.”

               To find out more visit StemCyte online at www.stemcyte.com.